Based in the UK and Belgium, the Apitope research team is develops peptide based therapeutics designed to selectively suppress aberrant interactions between immune cell and protein antigen, reinstating the body’s natural immune tolerance to the body’s own proteins.

This approach is founded on peer reviewed research demonstrating that treatment with a soluble, synthetic peptide derived from a known antigenic protein (such as myelin basic protein; a constituent of myelin) can prevent the immune system from responding to that protein as a threat.

The company has a patented discovery platform that it uses to identify and design unique peptide therapeutics.